Spondyloarthritis & psoriatic arthritis
Prevalence and Radiographic Progression of Hip Involvement in Patients With Ankylosing Spondylitis Treated With Tumor Necrosis Factor Inhibitors
Authors' conclusion
In our study, approximately one-third of patients with AS had hip involvement, which seemed to stabilize with TNFi treatment. No sex differences in the prevalence or progression of this manifestation were found.
Study context
- Population
- Patients with ankylosing spondylitis (AS) treated with TNFi (median age 43 yrs [IQR 36–52], median disease duration 7.6 yrs [IQR 2–15])263 assessed for progression
- Participants
- 299 patients
- Exposure
- Men vs women with AS treated with TNFi
- Malen = 215
- Femalen = 84reference
- Outcome
- Prevalence of hip involvement (BASRI-hip score ≥ 2) between sexes at baseline
- Follow-up
- Baseline
Methodological detailsBaseline radiographs (before TNFi) compared retrospectively with those after 2.5 (SD 0.7) and 7.0 (SD 2.3) years of TNFi
- Baseline radiographs (before TNFi) compared retrospectively with those after 2.5 (SD 0.7) and 7.0 (SD 2.3) years of TNFi
Main finding
As reported in the abstract
Hip involvement (BASRI-hip ≥ 2) at baseline
P = 0.10
- Overall prevalence of hip involvement at baseline
- 113/299 (38%)
Observational data: associations, not effects.
Further findings
Hip progression in patients with baseline hip involvement (BASRI-hip, mean joint space width (MJSW)) · 2.5 and 7.0 yrs
- BASRI-hip score and MJSW did not change significantly during follow-up in both sexes
Hip progression in patients without baseline hip involvement · 2.5 (SD 0.7) and 7.0 (SD 2.3) years
- BASRI-hip unchanged after 2.5 yrs but increased significantly after 7.0 yrs, without reaching the cut-off of 2
- MJSW slightly decreased at both follow-up timepoints
Spinal progression (modified Stoke AS Spinal Score (mSASSS))
- mSASSS increased significantly during follow-up in both sexes, regardless of hip involvement
Original publication
Prevalence and Radiographic Progression of Hip Involvement in Patients With Ankylosing Spondylitis Treated With Tumor Necrosis Factor Inhibitors. J Rheumatol. Published 1 November 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →